Pulmonary hypertension (PH) is a major complication of interstitial lung disease (ILD) and is associated with increased morbidity and mortality. Early recognition of PH in ILD is crucial for guiding diagnostic evaluation, initiating treatment, and considering lung transplantation.
Respected Zeder et al. report an interesting retrospective analysis of chronic obstructive pulmonary disease (COPD) patients with pulmonary hypertension (PH) finding that male sex was independently associated with higher mortality risk [1]. We commend the authors for addressing not differences, but note two methodological issues that merit discussion.
Pulmonary hypertension (PH) and diabetes frequently coexist, and metabolic dysregulation plays a role in PH pathogenesis. While preclinical studies indicate that certain antidiabetic therapies may beneficially impact the pulmonary vasculature and right heart function in PH, clinical data remain limited.
Pulmonary hypertension (PH) is a progressive condition associated with reduced physical activity and impaired quality of life. While exercise training is now recognised as a safe and beneficial adjunct to PH management, opportunities for supervised programmes remain limited.
The revised definition of pulmonary hypertension (PH) reclassifies patients previously diagnosed with chronic thromboembolic pulmonary disease (CTEPD) without pre-capillary PH as having chronic thromboembolic pulmonary hypertension (CTEPH).
Limited guidance exists for the management of methamphetamine-associated PAH (Meth-APAH) and the experiences of physicians treating this population are not well documented. This study explored how physicians approach diagnosis and treatment and identified unmet needs in clinical care through structured interviews with 30 U.S. pulmonologists and cardiologists who manage patients with Meth-APAH.
Pulmonary endarterectomy (PEA) is a potentially curative treatment for chronic thromboembolic pulmonary hypertension (CTEPH); however, decompensated right heart failure and concomitant cardiac procedures increase the risk of postoperative mortality.
Use of subcutaneous treprostinil (TRE) in children with pulmonary hypertension (PH) secondary to lung disease (group 3 PH) is not well described. We hypothesized that initiation of TRE is associated with improvement in PH severity and right ventricular (RV) function with minimal early side effects.
Pulmonary hypertension (PH) is a progressive and life-threatening disease characterized by pulmonary vascular remodeling that leads to elevated pulmonary artery pressures, and subsequent right ventricular dysfunction.
